We are excited to announce that Oregon Health & Science University (OHSU) in Portland is participating in an important study looking at a novel GLP-1/GIP agonist, CT-868, for glycemic control in overweight and obese people with type 1 diabetes (T1D).

CT-868 is similar to the medication Tirzepatide (Mounjaro), a GLP-1/GIP medication that the FDA approved for glucose and weight control in type 2 diabetes (T2D). Since there are no GLP-1/GIP agonists currently approved for T1D, studies like the CT-868 trial offer potential new ways to increase glucose control, improve weight management, and reduce long-term complications for those living with T1D.

Qualified Participants Must:

• Be a generally healthy adult with no tobacco use
• Have A1C levels between 7%-10%
• Be using a CGM within 3 months
• Have a BMI >27 and not be using any weight loss supplements within 6 months
• Have an insulin requirement of at least 0.6 units/kg/day

Additional criteria apply

Qualified Participants May:

• Receive access to study professionals
• Receive up to $1800 compensation for time and travel
• Have access to study medications

If you are interested, you can find additional details here for the novel GLP-1/GIP Study